Kymera Therapeutics, Inc. announced on May 9, 2025, the unveiling of KT-579, a new wholly-owned, first-in-class oral degrader program targeting IRF5. IRF5 is a historically undrugged transcription factor and master regulator of immunity, with strong genetic and clinical pathway validation across multiple autoimmune diseases such as lupus, Sjögren’s, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD).
Preclinical data for KT-579 demonstrated high potency and selectivity for IRF5, potent inhibition of pro-inflammatory cytokines and Type 1 interferon, and activity in lupus and RA animal models comparable or superior to existing standards of care. IND-enabling studies are ongoing, with Phase 1 clinical testing expected to begin in early 2026. This program strengthens Kymera’s immunology pipeline with a complementary mechanism.
Concurrently, Kymera reported its first-quarter 2025 financial results. Collaboration revenues increased significantly to $22.1 million from $10.3 million in Q1 2024, primarily due to a $20 million IRAK4 preclinical milestone payment. Research and development expenses rose to $80.3 million from $48.8 million, driven by increased investment in STAT6 and other immunology programs. The net loss for Q1 2025 was $65.6 million, compared to $48.6 million in Q1 2024.
As of March 31, 2025, Kymera held $775 million in cash, cash equivalents, and investments. This capital is projected to provide a cash runway into the first half of 2028, extending beyond multiple clinical inflection points. The company also made a strategic decision not to advance KT-295 (TYK2) into further clinical development, re-prioritizing investments to focus human and capital resources on the rapidly progressing STAT6 program and the new IRF5 program, which contributed to the extended cash runway.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.